News

Jubilant Life Sciences Limited announces approval of ‘JUBI-R’ (remdesivir) in India for the treatment of COVID-19

Jubilant’s Remdesivir product will be marketed under the brand name ‘JUBI-R’ in India and will be made available in 100 mg vials (injectable).

Read More

Jul 22, 2020

By : Team ABLE

Richcore LifeSciences to expand its recombinant protein manufacturing capability

Richcore’s expansion will go a long way in augmenting indigenous manufacturing of biomedical resources and strengthening domestic supply chain

Read More

Jul 22, 2020

By : Team ABLE

Serum Institute’s Adar Poonawalla hopes to launch COVID-19 vaccine by November

Mr Poonawalla had told NDTV that the vaccine will take probably two to two-and-half months to complete. He is hopeful that the vaccine will be launched by November, if the trials are positive and if the regulatorDCGI approves it.

Read More

Jul 22, 2020

By : Team ABLE

DBT and its research institutions accelerate development of covid-19 vaccines, therapeutics and diagnostics

The department is working relentlessly to mitigate COVID-19 crisis and they are deeply engaged in multifaceted R&D for offering potential COVID-19 solutions.

Read More

Jul 20, 2020

By : Team ABLE

UK signs deal to buy 30 million doses of COVID-19 vaccine from Pfizer & BioNTech

UK government move is to secure COVID-19 supplies due to likely delay in the Oxford vaccine development. These doses are expected to be delivered in 2020 and 2021, subject to regulatory approval or authorization

Read More

Jul 20, 2020

By : Team ABLE

 

BioEconomy Conclave 2026

24th February | TAJ MG Road, Bengaluru

Exhibit in the 'India Pavilion' at BIO 2026

June 22-25 | San Diego, USA

Focus Areas

Highlights